Induction of apoptosis in primary meningioma cultures by fenretinide

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1547-1553

  Puduvalli, Vinay K ^a   Li, Jessica T ^b   Chen, Ling ^a   McCutcheon, Ian E ^b  

^a Department of Neuro Oncology ^*  (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEATH RECEPTOR 5; FENRETINIDE; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR GAMMA; SOMATOMEDIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME DEGRADATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MENINGIOMA; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; FENRETINIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MEMBRANE POTENTIALS; MENINGIOMA; MITOCHONDRIA; POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE; RECEPTORS, RETINOIC ACID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RETINOID X RECEPTOR ALPHA; UP-REGULATION;

EID: 13944255418     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0786     Document Type: Article

References (30)

1. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996;29:197-205.
2. Kyritsis AP. Chemotherapy for meningiomas. J Neurooncol 1996;29:269-72.
3. McCutcheon IE. The biology of meningiomas. J Neurooncol 1996;29:207-16.
4. Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994;6:825-31.
5. De Palo G, Camerini T, Marubini E, et al. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 1997;83:884-94.
6. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997;20:36-9.
7. Decensi A, Bruno S, Costantini M, et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994;86:138-40.
8. Parchment RE, Jasti BR, Kocarek TA, et al. Pharmacologic issues for fenretinide chemotherapy (4HPR, NSC-374551). Clin Cancer Res 1999;5.
9. Garaventa A, Luksch R, Piccolo MSL, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-9.
10. Doose DR, Minn FL, Stellar S, Nayak RK. Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 1992;32:1089-95.
11. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999;55:403-10.
12. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl) retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
13. Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 1999;91:93-9.
14. Kleihues P, Cavenee WK. World Health Organization classification of tumors of the nervous system. Lyon: WHO/IARC;2000.
15. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000;60:6537-43.
16. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-55.
17. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:22441-6.
18. Hail N Jr, Lotan R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol Biomarkers Prev 2000;9:1293-301.
19. Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 1999;18:6380-7.
20. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001;6:377-88.
21. Boyd AS. An overview of the retinoids. Am J Med 2001;86:568-74.
22. Sheikh MS, Shao ZM, Li XS, et al. N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995;16:2477-86.
23. Delia D, Aiello A, Lombardi L, et al. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-41.
24. Moasser MM, DeBlasio A, Dmitrovsky E. Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor γ in human teratocarcinomas. Oncogene 1994;9:833-40.
25. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, Dmitrovsky E. Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene 1998;16:3471-80.
26. Kurihara M, Tokunaga Y, Tsutsumi K, et al. Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma. J Neurosurg 1989;71:538-44.
27. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992;50:215-22.
28. Lichtor T, Kurpakus MA, Gurney ME. Expression of insulin-like growth factors and their receptors in human meningiomas. J Neurooncol 1993;17:183-90.
29. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001;94:487-92.
30. Torrisi R, Pensa F, Orengo MA, et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993;53:4769-71.